Skip to main content
. Author manuscript; available in PMC: 2012 Apr 25.
Published in final edited form as: Inflamm Bowel Dis. 2008 Nov;14(11):1528–1541. doi: 10.1002/ibd.20512

TABLE 6A.

Multidimensionality Reduction (MDR) (IL23R as Dominant, IBD5, and ATG16L1 as Genotypic, NOD2 Not Considered)

No. of Markers Combinations Best Model Cross-Validation Consistency Prediction Error Significance, P-value (Based on 1000 Permutations)
1 IL23R_rs10889677a 10 0.40 0.007
2 IBD5_IGR2230, IL23R_rs10889677b 5 0.44 0.205
3 IBD5_IGR2198, ATG16L1, IL23R_rs10889677c 7 0.38 0.001
4 IBD5_IGR2198, ATG16L1, IL23R_rs2201841, IL23R_rs7517847d 7 0.39 0.003
a

IL23R_rs10889677 in dominant mode (AA/AC vs. CC).

b

IBD5_IGR2230 (rs17622208) in genotypic mode (AA, GA, GG); IL23R_rs108 (rs10889677) in dominant mode (AA/AC vs. CC).

c

IBD5_IGR2198 (rs11739135) in genotypic mode (GG, GC, CC); ATG16L1 (rs2241880) in genotypic mode (GG, AG, AA); IL23R_rs10889677 in dominant mode (AA/AC vs. CC).

d

IBD5_IGR2198 (rs11739135) in genotypic mode (GG, GC, CC); ATG16L1 (rs2241880) in genotypic mode (GG, AG, AA); IL23R_rs2201841 in dominant mode (CC/CT vs. TT); IL23R_rs7517847 in dominant mode (GG/TG vs. TT).